Holen Sie sich die Stockscreener-App
196.45
0.25%
0.49
Handel nachbörslich:
196.45
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Biogen Inc Aktie (BIIB) Neueste Nachrichten
BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm - Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc.BIIB - PR Newswire
Biogen receives FDA breakthrough designation for SMA therapy - Investing.com
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy - Biogen
UCB and Biogen build steroid-sparing case for lupus drug - The Pharma Letter
Biogen (BIIB) Presents Promising Data for Dapirolizumab Pegol at EULAR 2026 - GuruFocus
Mixed Lupus Win And Parkinson’s Setback Might Change The Case For Investing In Biogen (BIIB) - simplywall.st
Biogen Inc. stock (US09062X1037): Nasdaq shares steady as market digests Alzheimer’s drug outlook - AD HOC NEWS
Biogen Showcases Nephrology Advances with EMPAVELI® and Felzartamab at Major Medical Congresses - Quiver Quantitative
Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses - Biogen
Biogen Announces Upcoming Kidney Presentations at European - GlobeNewswire
Biogen Inc. stock (US09062X1037): shares firm after latest quarterly update and Alzheimer’s portfo - AD HOC NEWS
Biogen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
On the Edge of Drug Discovery - GW Today
Biogen Ends BIIB122 Parkinsons Trial And Refocuses Neurodegeneration Pipeline - Yahoo Finance
Biogen Inc. stock underperforms Monday when compared to competitors - MarketWatch
Lancet publication adds weight to UCB and Biogen lupus drug case - The Pharma Letter
(BIIB) Risk Channels and Responsive Allocation - Stock Traders Daily
Biogen (BIIB) Unveils Positive Phase 3 Findings for Dapirolizuma - GuruFocus
Biogen, UCB Say Lupus Drug Candidate Meets Primary Endpoint in Phase 3 Trial - marketscreener.com
Biogen Inc. (BIIB) Stock Analysis: A Closer Look At Its 11.96% Upside Potential - DirectorsTalk Interviews
Biogen (BIIB) Drug Trial Achieves Key Endpoint in Lupus Study - GuruFocus
UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus - Biogen
UCB and Biogen announce positive DZP phase 3 study results - marketscreener.com
A Look At Biogen (BIIB) Valuation After Earnings Beat And Parkinson’s Setback - simplywall.st
Biogen Inc. stock (US09062X1037): Italian antitrust probe and Parkinson’s trial halt in focus - AD HOC NEWS
Biogen and Denali halt BIIB122 trial for idiopathic Parkinson’s - Parkinson's News Today
Biogen investors urged to contact law firm over potential securities fraud claims. - Pluang
Why Is Biogen (BIIB) Up 3.8% Since Last Earnings Report? - Yahoo Finance
Biogen Faces Italian Investigation Over Blocking Sandoz’s Biosimilar Natalizumab - insights.citeline.com
symbol__ Stock Quote Price and Forecast - CNN
Should You Buy, Sell or Hold BIIB Stock After it Rises Almost 12% YTD? - TradingView
Biogen Inc. (BIIB) Investors with Losses are Urged to Contact The Gross Law Firm to Discuss Their Rights - GlobeNewswire
BIIB Stock Price, Quote & Chart | BIOGEN INC (NASDAQ:BIIB) - ChartMill
Biogen Inc. stock (US09062X1037): RBC price target lift and Italian antitrust probe in focus - AD HOC NEWS
Biogen Announces Webcast of Annual Meeting of Stockholders - Biogen
Bio-Rad Laboratories stock (US09062X1037): sector focus as Elliott stake and price gains keep NYSE l - AD HOC NEWS
Biogen under investigation by Italian authorities - medwatch.com
Biogen faces Italian antitrust probe over rivalry with Sandoz for MS drugs - MSN
BIIB Maintained by RBC Capital -- Price Target Raised to $227 - GuruFocus
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
RBC Capital Maintains Biogen(BIIB.US) With Buy Rating, Raises Target Price to $227 - Moomoo
RBC Lifts Price Target on Biogen to $227 From $222, Keeps Outperform Rating - Moomoo
Italy probes Biogen for allegedly hindering sales of rival's MS drug - Reuters
Italy probes Biogen for allegedly hindering sales of rival’s MS drug - WNWN-FM
RBC Capital raises Biogen stock price target on pipeline potential - Investing.com
Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh Cash Flow – BCBA:BIIB.CI - TradingView
Italian Watchdog Probes Biogen Over Alleged Effort to Block MS Biosimilar Rival - NAVLIN DAILY
RBC Capital raises Biogen stock price target on pipeline potential By Investing.com - Investing.com Canada
Discontinued operations of Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh – BCBA:BIIB.CI - TradingView
Debt to equity ratio of Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh – BCBA:BIIB.CI - TradingView
Diluted net income available to common stockholders of Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh – BCBA:BIIB.CI - TradingView
Biogen hit with Italian antitrust probe over multiple sclerosis market - MLex
Antitrust Authority Launches Investigation into Biogen for Multiple Sclerosis Drugs - Agenzia Nova
Italy's antitrust regulator opens probe into US Biogen over alleged dominant position - marketscreener.com
Biotech Growth Trust Portfolio Company Apellis To Be Acquired By Biogen - DirectorsTalk Interviews
Leqembi Isn't Enough To Save Biogen Momentum (Rating Downgrade) - Seeking Alpha
Biogen Inc. stock (US09062X1037): Alzheimer’s franchise and pipeline in focus after recent develop - AD HOC NEWS
Biogen Inc. (BIIB) Stock Analysis: Navigating a Potential 13% Upside Amidst Robust Drug Pipeline - DirectorsTalk Interviews
1.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):